NewsRx

Search our medical news database

Inflammatory Bowel Disease

Late-Stage Preclinical Results Of Growth Factor Are Promising

Published in Drug Week, November 23rd, 2001

CuraGen Corporation announced late-stage preclinical data on the novel growth factor, CG53135, which is being investigated for the treatment of inflammatory bowel disease.

This data was presented at the 66th Annual Scientific Meeting of the American College of Gastroenterology held in Las Vegas, Nevada, October, 2001.

CuraGen's CG53135 may have potential advantages over existing therapies for inflammatory bowel disease. Currently marketed drugs do not act directly to prevent the colon tissue damage present in patients diagnosed with this debilitating disease. In contrast, through its proliferative response on epithelial and mesenchymal cells,...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook